---
figid: PMC4383151__BMRI2015-548436.001
figtitle: Metformin action to inhibit cancer
organisms:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- clinical samples
- Bikinia letestui
organisms_ner:
- Homo sapiens
- Rattus norvegicus
- Mus musculus
- Danio rerio
pmcid: PMC4383151
filename: BMRI2015-548436.001.jpg
figlink: /pmc/articles/PMC4383151/figure/fig1/
number: F1
caption: Mechanisms of metformin action to inhibit cancer. Metformin disrupts circulating
  glucose and insulin levels and reduces inflammation. The organic cation transporter
  (OCT1) mediates the first step in metformin cellular response [–]. (1) Metformin
  activates the AMPK-P pathway through inhibition of Complex 1 of the mitochondrial
  respiratory chain [, ]. This leads to the inhibition of mTOR and thus loss of cell
  proliferation and inhibition of glucose synthesis [–]. (2) LKB1 may act as an intermediatory
  of AMPK activation [, ]. (3) Metformin blocks cAMP and PKA, which in turn antagonizes
  glucagon action []. (4) Metformin acts as an antifolate hindering DNA replication
  []. (5) Metformin induces an anti-inflammatory response via the Src-mediated NF-κΒ
  pathway []. (6) Metformin action is implicated in both AMPK dependent and independent
  inhibition of the angiogenesis process [].
papertitle: 'Recent Advances in the Use of Metformin: Can Treating Diabetes Prevent
  Breast Cancer?.'
reftext: Diana Hatoum, et al. Biomed Res Int. 2015;2015:548436.
year: '2015'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9363855
figid_alias: PMC4383151__F1
figtype: Figure
redirect_from: /figures/PMC4383151__F1
ndex: c9a80bb1-df07-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4383151__BMRI2015-548436.001.html
  '@type': Dataset
  description: Mechanisms of metformin action to inhibit cancer. Metformin disrupts
    circulating glucose and insulin levels and reduces inflammation. The organic cation
    transporter (OCT1) mediates the first step in metformin cellular response [–].
    (1) Metformin activates the AMPK-P pathway through inhibition of Complex 1 of
    the mitochondrial respiratory chain [, ]. This leads to the inhibition of mTOR
    and thus loss of cell proliferation and inhibition of glucose synthesis [–]. (2)
    LKB1 may act as an intermediatory of AMPK activation [, ]. (3) Metformin blocks
    cAMP and PKA, which in turn antagonizes glucagon action []. (4) Metformin acts
    as an antifolate hindering DNA replication []. (5) Metformin induces an anti-inflammatory
    response via the Src-mediated NF-κΒ pathway []. (6) Metformin action is implicated
    in both AMPK dependent and independent inhibition of the angiogenesis process
    [].
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - SRC
  - FGR
  - FYN
  - YES1
  - NFKB1
  - POU2F1
  - SLC22A1
  - PLXNA2
  - STK11
  - ATP8A2
  - APRT
  - MFAP1
  - PRKAA1
  - PRKAA2
  - PRKAB1
  - PRKAB2
  - PRKAG1
  - PRKAG2
  - PRKAG3
  - MTOR
  - PRKAR1A
  - PRKAR1B
  - PRKAR2A
  - PRKAR2B
  - PRKACA
  - PRKACB
  - PRKACG
  - Src
  - Nfkb1
  - Slc22a1
  - Stk11
  - Tmprss5
  - Prkaa2
  - Mtor
  - Pou2f1
  - Plxna2
  - src
  - pou2f1a
  - slc22a2
  - stk11
  - mtor
  - Folate
  - Glucose
  - Metformin
---
